U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. News & Events
  3. FDA Meetings, Conferences and Workshops
  4. •FDA - Duke Accelerating Anticancer Agent Development and Validation Workshop (AAADV) - 05/08/2019 - 05/10/2019
  1. FDA Meetings, Conferences and Workshops

Workshop | In Person

Event Title
•FDA - Duke Accelerating Anticancer Agent Development and Validation Workshop (AAADV)
May 8 - 10, 2019

Scheduled
Date:
May 8 - 10, 2019

Co-Sponsored by the:
U.S. Food & Drug Administration (FDA) Oncology Center of Excellence and
Duke University

Date:  May 8 - 10, 2019

Time:  8:00 am to 5:30 pm - May 8, 2019
           8:00 am to 6:00 pm - May 9, 2019
           8:00 am to 12:00 pm - May 10, 2019

Location:  Bethesda North Marriott Hotel and Conference Center
                 5701 Marinelli Road
                 Rockville, MD 20852 

Registration: https://whova.com/portal/registration/aaw_201905/ 

Background:

This workshop provides a forum for discussion of anti-cancer agent development and imparts the knowledge necessary to enable successful early-career clinical researchers to become expert in the entire spectrum of drug development. 
 

Workshop Objectives:

  • Expedite the development and validation processes for new anticancer and cancer prevention agents.
  • Educate investigators, so new agents may be made available to patients at a more efficient rate more rapidly in the future.
  • Improve understanding of cancer drug development strategies to lead to a series of pivotal clinical trials demonstrating efficacy and patient benefit.

Who Should Attend:

  • Industry: Registrants should be involved in drug development.
  • Government: Registrants should be employed by a U.S. government agency and be involved in oncology drug discovery or development. 
  • Academic: Registrants should be employed by a recognized academic institution and be involved or have an interest in oncology drug discovery and/or development. Previous or current experience in the conduct of clinical trials is helpful, but not required.
  • Advocates: Consumer and/or patient advocates should be sponsored by a nationally recognized advocacy organization or foundation. Advocates should have a background in clinical trial design and the role of the advocate in the development process.

Meeting Information:  Available at https://aaadv.org/

Contact:

If to Duke:     Brenda Cash-Hamlin
Brenda.cashhamlin@aaadvworkshop.org  
(919) 579-3111

If to FDA:      Valerie Vashio
Valerie.Vashio@fda.hhs.gov
(301) 796-3710

 

Back to Top